Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
Metastatic human epidermal growth factor 2 positive carcinoma of breast
0.010 Biomarker disease BEFREE This phase I/II dose-escalation study investigated the maximum tolerated dose (MTD), safety, pharmacokinetics, and efficacy of the pan-class I phosphoinositide 3-kinase inhibitor pilaralisib in combination with trastuzumab (Arm 1) or trastuzumab plus paclitaxel (Arm 2) in patients with HER2-positive metastatic breast cancer. 25537644 2015